Information Provided By: 
Fly News Breaks for April 27, 2016
AGN
Apr 27, 2016 | 08:53 EDT
UBS said Allergan should be a core holding again, citing management's defense of Botox and its continued investment in a solid pipeline. The firm also likes the risk/reward at current levels, its impressive growth profile, and its potential for even better growth. UBS reiterated its Buy rating and $300 price target on Allergan shares.
News For AGN From the Last 2 Days
There are no results for your query AGN
